LianBio (LianBio) Interest Coverage : N/A (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LianBio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. LianBio's Operating Income for the three months ended in Sep. 2023 was $-26.30 Mil. LianBio's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. LianBio has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for LianBio's Interest Coverage or its related term are showing as below:

LIANY's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LianBio Interest Coverage Historical Data

The historical data trend for LianBio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LianBio Interest Coverage Chart

LianBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Interest Coverage

N/A

LianBio Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Coverage	Get a 7-Day Free Trial										N/A	N/A	N/A	N/A	N/A

Competitive Comparison of LianBio's Interest Coverage

For the Biotechnology subindustry, LianBio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LianBio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LianBio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where LianBio's Interest Coverage falls into.

LianBio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LianBio's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, LianBio's Interest Expense was $0.00 Mil. Its Operating Income was $-125.35 Mil. And its Long-Term Debt & Capital Lease Obligation was $2.49 Mil.

GuruFocus does not calculate LianBio's interest coverage with the available data.

LianBio's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, LianBio's Interest Expense was $0.00 Mil. Its Operating Income was $-26.30 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.95 Mil.

GuruFocus does not calculate LianBio's interest coverage with the available data.

The higher the ratio, the stronger the company's Financial Strength is.

LianBio (OTCPK:LIANY) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

LianBio Interest Coverage Related Terms

Thank you for viewing the detailed overview of LianBio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

LianBio (LianBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LianBio (OTCPK:LIANY) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Carnegie Center Drive, Suite 215, Princeton, NJ, USA, 08540

Website

https://www.lianbio.com

LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications.

Executives

Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Wei Wei Chen	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 309, PRINCETON NJ 08540
Debra Yu	officer: See Remarks	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
C2 Life Sciences Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Lev Lb Holdings Gp, Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Venture Advisors, Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Brianne Jahn	officer: Chief Business Officer	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Yizhe Wang	director, officer: Chief Executive Officer	103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Jiang Qian	officer: China General Manager	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lev Lb Holdings, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Xontogeny Venture Fund, Lp	10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Yi Larson	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Neil Kumar	director	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304